ReviewCurrent neurology and neuroscience reports2026
Dystonia: Insights into Mechanisms and Novel Therapeutics.
Review in Current neurology and neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewDystonia is a highly heterogeneous movement disorder with complex molecular underpinnings. This review aims to synthesize insights into pathophysiological mechanisms driving dystonia with emphasis on latest advances. RECENT
findingsIn recent years, key molecular pathways in dystonia have been elucidated, among them: aberrant transcriptional regulation, altered protein turnover, nuclear envelope dysfunction, and mitochondrial impairment. Emerging data reveal the interplay and convergence of some of these disease-related processes, highlighting overarching molecular vulnerabilities critical to pathogenesis. Deciphering molecular mechanisms underlying dystonia facilitates the stratification of affected individuals into biologically defined subgroups, which will be essential for the development of targeted therapies. Patient assessment based on individual molecular profiles represents a promising avenue for future therapeutic and preventive strategies in dystonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.